Liraglutide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Liraglutide

Also known as: Saxenda, Victoza, GLP-1 analogue, GLP-1 receptor agonist, incretin mimetic

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Research chemicalLast updated: October 31, 2026Based on 38 peer-reviewed studies

What it is

Liraglutide is the active ingredient in Victoza (type 2 diabetes) and Saxenda (obesity), FDA-approved drugs for blood sugar control and weight loss. It works by mimicking a gut hormone to curb appetite and regulate insulin. Prescription only; also studied for cardiovascular protection and fatty liver disease.

The scientific side

Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue with 97% amino acid homology to native GLP-1. It acts as a GLP-1 receptor agonist, binding to the GLP-1 receptor to improve fasting and postprandial glycaemic control via glucose-dependent increases in insulin secretion and reductions in glucagon levels, with minor delays in gastric emptying. Liraglutide also reduces appetite and energy intake, and has effects on postprandial lipid profiles. Its prolonged action (half-life approximately 13 hours) is attributable to slowed release from the injection site, reduced elimination via metabolic stabilisation, and reduced renal filtration, enabling once-daily dosing. Beyond glycaemic effects, liraglutide activates HCN channels in pancreatic islets to augment calcium oscillation frequency and insulin secretion, inhibits NF-κB phosphorylation, activates AMPK to enhance lipophagy, modulates macrophage polarization via PI3K/AKT and STAT3/6 pathways, promotes neuroplasticity and reduces neuroinflammation, and exerts antioxidant and anti-apoptotic effects.

Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Legal & regulatory status

US FDA

Approved for treatment of type 2 diabetes and obesity (cited as approved for weight management under brand name Saxenda, and for T2DM; PMID: 26074046, 28701318). Specific approval dates and full label indications…

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification